

1 Dalmore Drive,
Scoresby,
Victoria 3179
AUSTRALIA
T: +61 (0)3 9763-1287
F: +61 (0)3 9763-2817
www.generabiosystems.com

Friday 31 August 2018

**ASX Announcement – GENERA BIOSYSTEMS LIMITED (ASX: GBI)
GENERA – KEY EXECUTIVE APPOINTMENTS & CAPITAL STRUCTURE UPDATE**

Genera Biosystems Limited (ASX:GBI) ('Genera' or 'the Company') announces that it has appointed Mr Seong Chen and Dr Damian Pethica to its Executive Leadership Team.

Both Seong and Damian have a deep background in areas relevant to Genera's commercialisation strategy, specifically in HPV and drug development and precision medicine. Chairman, Lou Panaccio commented "We are delighted to secure the services of both Seong and Damian. They will provide invaluable support to our CEO, Richard Hannebery, in helping drive additional high value partnering deals. Genera has a wide field of commercial opportunity that builds upon the strong foundation provided by the Beckman Coulter Distribution Agreement announced earlier this year and I am confident that building out our senior team with these key additions will assist in executing on this opportunity."

Genera CEO, Richard Hannebery added, "Due to our ability to multiplex 30 to 40 or more targets in a single-well of a reaction plate, we have always thought that our proprietary AmpaSand® test platform was uniquely placed for the development of high value companion diagnostics for the delivery of precision medicine. Seong and Damian have backgrounds and expertise that position them ideally to add value to Genera. Securing them is an absolute coup for our company and shareholders alike. Both have a deep understanding of the HPV market which is highly relevant to our lead test, PapType®. I look forward to working with them to drive forward our strategy for PapType®, which is a well validated next generation HPV assay. In addition to their HPV expertise Seong and Damian's background will also assist in our push into the companion diagnostic (CDx) testing space."

Seong J Chen BEng, MBA – Director Corporate Development

Seong Chen started at Roche Diagnostics Chief Technology Office (Berkeley, CA) in 2002 as Technology Analyst where he examined the potential competing technologies for PCR such as isothermal technologies.

Subsequently as a Finance Manager (Pleasanton, CA), Seong helped develop and evaluate the go-to-market strategy for Roche's HPV franchise. After spending 5 years in Pricing and Finance in Pleasanton, Seong relocated to Rotkreuz, Switzerland in 2007 to lead the Strategic Pricing & Commercial Affairs group at Roche Professional Diagnostics. In this role, Seong has developed pricing strategies and supported many new product launches, including transfer pricing negotiation with corporate partners on instruments and consumables. In April 2011, Seong was appointed the Project Leader in Roche Diagnostics, Basel, Switzerland to lead a division initiative in Pricing & Reimbursement. In this role Seong assessed the market access strategy for leading products in selected key countries. Since the end of 2014, Seong moved to a newly created position for companion diagnostics (CDx) commercialisation, where he collaborated with pharmaceutical

companies in developing commercial strategies - including market access - for CDx applications in key markets. Seong left Roche in May 2018 and relocated with his family back to Australia in July.

Seong completed the Electrical Engineering study at University of Melbourne, Australia with First Class Honours, and received a MBA from University of Berkeley, California. Prior to Roche, Seong worked at Schlumberger and Boston Consulting Group.

Dr Damian Pethica MA(Oxon), MBBS, FFPM – Chief Medical Officer

Damian initially worked for six years with the Pharmaceutical Division of Ciba-Geigy in Basel, Switzerland. In Basel he held roles as Medical Affairs Group Head of Oncology as well as Medical Adviser – Cardiovascular. After his time in Basel, Damian was promoted to the role of Medical Director of Ciba-Geigy/Novartis New Zealand, with responsibilities including registration, clinical development, pharmacoepidemiology and medical support for reimbursement negotiations.

He left Novartis to join Robert Flemings and then JP Morgan Chase, based in London as Vice President and Head of Biotechnology Equity Research Europe. After JP Morgan Chase Damian returned to New Zealand to live and has since undertaken a variety of specialist advisory and consulting roles in both New Zealand and Australia. He was a member of the NZ Medicines Assessment Advisory Committee from 2002-2015, which has a role similar to the US FDA Advisory Committees for pharmaceuticals, and remains a current member of the NZ Standing Committee on Therapeutic Trials, which undertakes scientific reviews of proposed clinical trials of medicines in parallel with Ethics review. Many cancer clinical trials include exploratory genomics, with the goal of developing a Companion Diagnostic (CDx) to optimise efficacy. Damian has consulted in the healthcare insurance sector, drafting guidelines and implementing decision making processes for the reimbursement of new medical technologies. Damian is also an Honorary Senior Lecturer, Epidemiology and Biostatistics, Auckland University, and is performing a tissue-based study reassessing the potential role of HPV in prostate cancer.

Damian studied mathematics at Oxford University, with BA First Class Honours, and then medicine at University College Hospital, London with MBBS followed by 7 years of clinical practice experience including anaesthetics and general practice. He is a Fellow of the Faculty of Pharmaceutical Physicians, Royal College of Physicians, London.

Non-Renounceable Entitlements Issue

Genera is on track to lodge a prospectus with ASIC the week of 14 September to raise up to \$11.2M via a 4 for 5 non-renounceable entitlements issue at an Issue Price of \$0.13 per new share (the “**Entitlements Issue**”). The proposed Entitlements Issue is currently anticipated to close the first week of October and is aimed to strengthen the Company’s financial position and support the planned rollout of Genera’s test menu operating on the new automated Beckman Coulter system, an expansion of Genera’s test development and commercialisation teams and an expansion of the AmpaSand test menu.

Correction to FY2017 Accounts and lodgement of FY2018 Appendix 4E Accounts

During the process of preparing for the Company’s Entitlements Issue Prospectus, an error in relation to the interest amounts accrued for the Series B Convertible Notes has been identified. This error relates to the calculation of the interest amounts payable which were previously calculated using an annual interest mount payable of 30% but should have been calculated on an IRR basis. As at 30 June 2018 the total amount outstanding to Series B Convertible Note holders was \$7.2m.

Genera will lodge its Appendix 4E with ASX pre-market Monday 3 September.

For further information please contact:

Mr Richard Hannebery
Chief Executive Officer
Genera Biosystems Limited
Telephone: +61 (0)3 9763 1287
www.generabiosystems.com.au

About Genera Biosystems : Genera Biosystems Limited (“GBI”) is an Australian Securities Exchange listed molecular diagnostics company, which develops, manufactures and distributes advanced PCR molecular diagnostics tests.

Genera’s single-well high multiplex AmpaSand® testing platform can detect up to 125 target analytes in a single-well of a reaction plate. Unlike traditional real-time PCR approaches, AmpaSand® single-well multiplex tests when run on a seamlessly integrated flow cytometry and liquid handling system can provide unparalleled throughput capability and cost efficiency for high volume pathology laboratories qualitative molecular testing needs.¹

Genera manufactures products in its Australian Therapeutics Goods Administration certified manufacturing facility in Scoresby, Victoria, Australia.

PapType®, an ARTG listed and CE-marked MDx test, simultaneously detects and identifies 14 high-risk types of HPV and 2 low risk HPV types in a single-well. These high-risk HPV types are responsible for 99.7% of all cases of cervical cancer.

In addition to PapType®, Genera has also commercialized and gained ARTG listing and CE mark for RTIplex™, a single-well multiplex MDx that identifies 15 common upper respiratory tract pathogens, including Influenza A & B, as well as 10 other viral and 3 bacterial disease-causing microbial targets.

Genera’s development pipeline includes a new 8-plex sexually transmitted infections panel that is expected to be available in the 2nd half of 2018, with plans to broaden the AmpaSand® test menu further to 6 highly competitive single-well multiplex MDx assays by 2019.

PapType®, RTIplex™, and the tests in development, employ the AmpaSand® biochemistry as well as Genera’s proprietary ARTG listed and CE-IVD marked QPlots™ automated analytical and reporting software that is compatible with most Laboratory Information Management Systems (‘LIMS’).

All the components of the Genera MDx system, including AmpaSand® and QPlots™, have been optimized to run on Beckman Coulter’s innovative CytoFLEX™ flow cytometry system.

¹ All ‘plate based’ Real Time PCR platforms can ‘multiplex’ up to 4 targets per well assuming 4 available channels of a Real Time PCR instrument. To multiplex greater than 4 target analytes in a test most platforms require use of additional wells of a plate to test for the additional target analytes. As such commercially, their multiplexing capability is restricted due to a direct trade-off with volume throughput per plate (96 or 384 well). Genera’s AmpaSand® technology facilitates the multiplexing of up to ~125 target analytes **in a single-well** of a plate. On a like for like basis depending on the number of target analytes detected in a multiplex assay Genera’s AmpaSand® technology facilitates > 4X relative volume throughput. High volume throughput is a key commercial consideration for all large pathology labs undertaking HPV and STI testing.